clinical trial · NCT06149559
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
UCB Biopharma SRL·phase3·recruiting·n = 12
Generalized Myasthenia Gravisrozanolixizumab
brief summary
The purpose of the study is to assess the safety and tolerability of subcutaneous (sc) administration of rozanolixizumab in pediatric participants aged ≥2 to \<18 years with generalized Myasthenia Gravis (gMG).
started
Jun 14, 2024
primary completion
Jun 8, 2026
completion
Aug 17, 2026
last updated
Apr 24, 2026
official title
An Open-label, Single-arm Study Evaluating the Activity, Safety, and Pharmacokinetics of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol